High Court’s Wyeth v. Levine Ruling Returns Pre-Emption Status Quo
This article was originally published in The Tan Sheet
The Supreme Court's ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from state product liability lawsuits, but is not expected to trigger a sea-change in current industry operations
You may also be interested in...
Review makes clear FDA’s thinking on safety acetaminophen use during pregnancy, but likely won’t sway federal judge from her conclusion that a warning about risks of in utero exposure could be added to drug containing the ingredient and available under an OTC monograph without violating FDA regulations.
Ruling on pre-trial motion in complaint against a Kenvue business in District Court for Southern New York is first in litigation alleging damages from using OTC monograph drug to find against federal preemption of state consumer protection laws and similar regulations.
A federal judge rejected an argument that FDA’s regulation of homeopathic drugs pre-empts a state consumer protection law.